VXA-CoV2-1.1-S
Alternative Names: S only COVID-19 vaccine; S-only Wuhan vaccine - VaxartLatest Information Update: 18 Jun 2024
At a glance
- Originator Vaxart
- Class COVID-19 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 13 Jun 2024 Vaxart plans a phase-IIb trial for COVID-2019 infections (Prevention) in the third quarter of 2024
- 22 Jan 2024 Vaxart collaborates with Biomedical Advanced Research and Development Authority for phase IIb trial in Covid-19 infections
- 01 Aug 2023 Vaxart completes the phase II trial in COVID-19 infections (Prevention) in USA (NCT05067933)